title: Lansoprazole elevates the ratio of serum pepsinogen I v.s. pepsinogen II.
abstract: In order to investigate the mechanism by which proton pump inhibitor increases serum pepsinogen levels, we evaluated the effects of ulcer location and IgG antibody against Helicobacter pylori on lansoprazole-induced elevations. Patients with endoscopically proven peptic ulcer received lansoprazole 30 mg/day for 6 or 8 weeks; pepsinogen I and II levels, along with antibody to H. pylori, were measured in fasting blood samples. We found that whether or not antibody to H. pylori was present, pepsinogen I and II levels and the I/II ratio rose significantly in lansoprazole-treated patients. Patients with stomach-body ulcers showed smaller increases in both pepsinogens than did those with ulcers in the gastric angle/antrum or in the duodenum. In conclusion, lansoprazole increases serum levels of both pepsinogens I and II, although a larger increase in pepsinogen I elevates the pepsinogen I/II ratio. The relatively small increases seen in patients with stomach-body ulcers suggest atrophic changes in the gastric mucosa in patients with stomach-body ulcer.
authors.affiliation: First Department of Internal Medicine, Nihon University School of Medicine, Tokyo, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Matsukawa
authors.forename: S
authors.initials: S
authors.lastname: Nishinarita
authors.forename: M
authors.initials: M
authors.lastname: Kaneko
authors.forename: M
authors.initials: M
authors.lastname: Takei
authors.forename: M
authors.initials: M
authors.lastname: Murakami
authors.forename: T
authors.initials: T
authors.lastname: Horie
authors.forename: F
authors.initials: F
authors.lastname: Kawamura
authors.forename: Y
authors.initials: Y
authors.lastname: Arakawa
authors.forename: H
authors.initials: H
authors.lastname: Kuwayama
authors.forename: H
authors.initials: H
authors.lastname: Kurosaka
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000328:Adult; D000368:Aged; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D016481:Helicobacter Infections / Q000150:complications / Q000188:drug therapy; D016480:Helicobacter pylori / Q000276:immunology; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood; D064747:Lansoprazole; D008875:Middle Aged; D009853:Omeprazole / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010435:Pepsinogens / Q000097:blood*; D010437:Peptic Ulcer / Q000097:blood / Q000150:complications / Q000188:drug therapy*
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D007074:Immunoglobulin G; D010435:Pepsinogens; D064747:Lansoprazole; D009853:Omeprazole